Veracyte (VCYT) Fundamentals 2026 — P/E 52.6x, Revenue Analysis | SniperIQ
Veracyte (VCYT) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $4.7B, trading at $58.30 on the NASDAQ. This SniperIQ fundamentals page covers Veracyte's valuation (P/E 52.6x, P/B 3.4x), profitability (net margin 16.2%), revenue ($517M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Veracyte's market cap?
Veracyte (VCYT) has a market capitalization of approximately $4.7B, trading at $58.30 on the NASDAQ. Market cap moves with the live share price.
What is Veracyte's P/E ratio?
Veracyte's trailing twelve-month P/E ratio is 52.6x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Veracyte?
Veracyte runs a net profit margin of 16.2%, a gross margin of 71.3%, and an operating margin of 12.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Veracyte generate?
Veracyte reported revenue of $517M for fiscal year 2025, with net income of $66M and earnings per share (EPS) of 0.84. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Veracyte pay a dividend?
Veracyte does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Veracyte financially healthy?
Veracyte carries a debt-to-equity ratio of 0.03x and a current ratio of 9.31x, with a market beta of 1.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Veracyte a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Veracyte (VCYT) the key facts are: market cap $4.7B, P/E 52.6x, revenue $517M, 52-week range 22.92-60.91. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Veracyte's full fundamentals live
Get Veracyte's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.